Skip to main content

Table 3 Univariate analysis of metastases-free survival (MFS)

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

  At 1 year (%) At 3 years (%) P
Radiochemotherapy regimen
 Cisplatin weekly (N = 75) 89 68  
 Cisplatin 100 mg/m2 (N = 58) 83 76 0.66
Age
 ≤56 years (N = 67) 85 71  
 ≥57 years (N = 66) 88 72 0.30
Gender
 Female (N = 29) 79 69  
 Male (N = 104) 89 72 0.59
ECOG Performance score
 0–1 (N = 115) 92 79  
 2 (N = 18) 52 25 <0.001
Primary tumor site
 Oropharynx (N = 69) 89 78  
 Hypopharynx (N = 19) 71 61  
 Larynx (N = 30) 100 77  
 Oral cavity/Floor of mouth (N = 15) 62 44 0.002
T-category
 T1–2 (N = 16) 93 85  
 T3–4 (N = 117) 85 69 0.93
N-category
 N0-2a (N = 66) 97 81  
 N2b-3 (N = 67) 76 62 0.001
Histologic grading
 G 1–2 (N = 85) 95 76  
 G3 (N = 48) 72 63 0.003
Cumulative cisplatin dose
 ≤200 mg/m2 (N = 85) 87 71  
 >200 mg/m2 (N = 48) 86 73 0.69
  1. After Bonferroni correction for multiple tests, p-values of <0.006 were considered significant
  2. Bold values represent significant p-values